share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：諾和諾德-股票回購計劃
美股SEC公告 ·  07/22 23:16
牛牛AI助理已提取核心訊息
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
2024年7月22日，總部位於丹麥的全球醫療保健領導者Novo Nordisk A/S在其股票回購計劃方面取得了進展。該計劃是DKK 200億回購計劃的一部分，該計劃於2024年2月6日開始，爲期12個月。公司在2024年5月7日至8月5日期間回購了DKK 22億的B股股份。自7月15日最新進展以來，Novo Nordisk以平均價格DKk 941.45收購了1869670億股，總計DKk 175,979,457。總體而言，在2024年2月6日回購期開始以來，公司已以DKk 878.31的平均價格回購了106190370億股，總金額爲DKk 9,326,780,889。這些交易將公司的庫藏股份增加到119848270億股，佔股本的0.3%。Novo Nordisk的股票在納斯達克科普寧和紐約證券交易所上市，分別使用“Novo-B”和“NVO”代號。
2024年7月22日，總部位於丹麥的全球醫療保健領導者Novo Nordisk A/S在其股票回購計劃方面取得了進展。該計劃是DKK 200億回購計劃的一部分，該計劃於2024年2月6日開始，爲期12個月。公司在2024年5月7日至8月5日期間回購了DKK 22億的B股股份。自7月15日最新進展以來，Novo Nordisk以平均價格DKk 941.45收購了1869670億股，總計DKk 175,979,457。總體而言，在2024年2月6日回購期開始以來，公司已以DKk 878.31的平均價格回購了106190370億股，總金額爲DKk 9,326,780,889。這些交易將公司的庫藏股份增加到119848270億股，佔股本的0.3%。Novo Nordisk的股票在納斯達克科普寧和紐約證券交易所上市，分別使用“Novo-B”和“NVO”代號。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。